Manish Sharma, MD
Medical Oncology · Grand Rapids, MINPI 1790819332
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.9%), consulting fees and education — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Aadi Bioscience, Inc. at 45.6% of the total. 2025 is the largest year on record at $1,856, 2.8 times the $660 reported in 2019.
Across 122 payments — averaging $42.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aadi Bioscience, Inc.$2K
- Foundation Medicine, Inc.$295
- Novartis$266
- Ipsen Biopharmaceuticals, Inc$247
- Theratechnologies Inc.$224
- Merck$183
- plus $2K from 33 others
Across 2,646 payments — averaging $7194.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$7.1M
- AbbVie$3.7M
- Merck$2.1M
- Exelixis Inc.$1.2M
- Tesaro, Inc.$951K
- E.r. Squibb & Sons, L.L.C.$907K
- plus $3.1M from 12 others
What the payments were for
- Consulting fees$2,36346%
- Food & beverage$2,79454%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aadi Bioscience, Inc. | 3 | $2,363 |
| Foundation Medicine, Inc. | 5 | $295 |
| Novartis | 10 | $266 |
| Ipsen Biopharmaceuticals, Inc | 6 | $247 |
| Theratechnologies Inc. | 2 | $224 |
| Merck | 4 | $183 |
| AstraZeneca(2 entities) | 8 | $158 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $146 |
| Pfizer | 12 | $143 |
| Incyte Corporation | 7 | $122 |
| Genentech USA, Inc. | 8 | $122 |
| Bayer | 5 | $78 |
| AbbVie | 4 | $72 |
| Genmab U.S., Inc. | 1 | $64 |
| EMD Serono, Inc. | 4 | $59 |
| Seagen Inc. | 3 | $54 |
| Exelixis Inc. | 3 | $51 |
| Lilly USA, LLC | 3 | $47 |
| Eisai Inc. | 2 | $46 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| Amgen | 2 | $38 |
| Astellas Pharma US Inc | 2 | $35 |
| Rigel Pharmaceuticals, Inc. | 2 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Myovant Sciences Inc. | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Adaptive Biotechnologies Corporation | 1 | $21 |
| Taiho Oncology, Inc. | 1 | $19 |
| Beigene USA, Inc. | 1 | $19 |
| Spectrum Pharmaceuticals Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $14 |
| Tesaro, Inc. | 1 | $14 |
| Novo Nordisk | 1 | $13 |
| Servier Pharmaceuticals LLC | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| ADC Therapeutics America, Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FYARRO$1,838
- FOUNDATIONONE$241
- FOUNDATIONONE HEME$241
- FOUNDATIONONE CDX$241
- FOUNDATIONFOCUS$241
- FOUNDATIONONE LIQUID$241
- EGRIFTA$128
- TROGARZO$128
- ONIVYDE$125
- KEYTRUDA$114
How this compares
$5,181 in reported general payments places this provider in the 60th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $11,713 |
| Fentanyl | 11 | $1,443 |
| Oxycodone Hcl | 12 | $462 |
| Duloxetine Hcl | 18 | $238 |
| Prochlorperazine Maleate | 14 | $185 |
| Amlodipine Besylate | 26 | $166 |
| Potassium Chloride | 22 | $120 |
| Levothyroxine Sodium | 11 | $81 |
| Prednisone | 16 | $41 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $143 | $11,71320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 170 medical oncology providers in Michigan.
Other medical oncology in Grand Rapids
- Sami BrakeGrand Rapids$251K
- Anas AljanadiGrand Rapids$62K
- Manish ThakurGrand Rapids$17K
- Zeyad SakoGrand Rapids$10K
- Harry ErbaAnn Arbor$1.1M
- Philip PhilipDetroit$494K
- Shirish GadgeelDetroit$413K
- Patricia Lo RussoDetroit$322K
- Ammar SukariDetroit$273K
- Frank WeinbergAnn Arbor$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.